Court Ruling in Favor of Aquestive Therapeutics Enjoining Dr. Reddy's Laboratories from Launching its Generic Suboxone Product

Monday, July 16, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Aquestive Granted Preliminary Injunction

WARREN, N.J., July 16, 2018 /PRNewswire/ -- Aquestive Therapeutics

("Aquestive") announces today that the U.S. District Court for the District of New Jersey has granted Aquestive together with Indivior PLC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against
Dr. Reddy's Laboratories ("DRL"), mandating the restrictions of the previously entered temporary restraining order (TRO) remain in place. The preliminary injunction prevents DRL from using, selling, offering to sell, or importing its generic buprenorphine/naloxone sublingual film until further order of the district court or of the appellate court.  At issue in the underlying preliminary injunction proceedings was, among other things, the infringement of U.S. Patent No. 9,931,305 (known as the "305 patent") by DRL. 

Keith J. Kendall, CEO of Aquestive, said: "This decision once again demonstrates the significant value our intellectual property has created for Aquestive, its products and our partners." He added, "We continue to believe that DRL's challenge to our patents is without merit."

About Aquestive Therapeutics

Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. For more information, please visit our website, aquestive.com.

Media inquiries:Christopher Hippolytechristopher.hippolyte@syneoshealth.com212-364-0458

Investor inquiries:Stephanie Carringtonstephanie.carrington@icrinc.com646-277-1282

Cision View original content:http://www.prnewswire.com/news-releases/court-ruling-in-favor-of-aquestive-therapeutics-enjoining-dr-reddys-laboratories-from-launching-its-generic-suboxone-product-300681098.html

SOURCE Aquestive Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store